FGFR3 elisa kit

FGFR3 Colorimetric Cell-Based ELISA Kit

Cat. Num. AAA9500226

• Gene Names: FGFR3; ACH; CEK2; JTK4; CD333; HSFGFR3EX
• Reactivity: Human, Mouse, Rat
• Synonyms: FGFR3; FGFR3 Colorimetric Cell-Based ELISA Kit; FGFR-3; CD333 antigen; Fibroblast growth factor receptor 3; JTK4; CD333; FGFR3 elisa kit

• Reactivity: Human, Mouse, Rat
• Specificity: The Anti-FGFR3 Antibody is a rabbit polyclonal antibody. It was tested on Western Blots for specificity. The data in Figure 2 shows that a single protein band was detected. This protein band can be blocked by the synthesized immunogen peptide.
• Form/Format: One 96-Well Plate
• Sequence Length: 806

• Preparation and Storage: Store at 4 degree C.

Related Product Information for FGFR3 elisa kit

Background/Introduction: The Colorimetric Cell-Based ELISA Kit allows for the detection of various target proteins and the effects that certain stimulation conditions have on target protein expression in different cell lines. Qualitative determination of target protein concentration is achieved by an indirect ELISA format. In essence, the target protein is captured by target-specific primary (1 degree) antibodies while the HRP-conjugated secondary (2 degree) antibodies bind the Fc region of the 1 degree antibody. Through this binding, the HRP enzyme conjugated to the 2 degree antibody can catalyze a colorimetric reaction upon substrate addition. Due to the qualitative nature of the Cell-Based ELISA, multiple normalization methods are described: 1) a monoclonal antibody specific for human GAPDH is included to serve as an internal positive control in normalizing the target absorbance values. 2) Following the colorimetric measurement of HRP activity via substrate addition, the Crystal Violet whole-cell staining method is used to determine cell density. After staining, the results can be analyzed by normalizing the absorbance values to cell amounts, by which the plating difference can be adjusted. 3) If a phosphorylated target is being detected, an antibody against the non-phosphorylated counterpart will be provided for normalization purposes. The absorbance values obtained for the non-phosphorylated target can be used to normalize the absorbance values for the phosphorylated target.

Product Categories/Family for FGFR3 elisa kit

Cell Based ELISA Kit

NCBI and Uniprot Product Information

• NCBI GI #: 4503711
• NCBI GeneID: 2261
• NCBI Accession #: NP_000133.1
• NCBI GenBank Nucleotide #: NM_000142.4
• UniProt Accession #: P22607; Q14308; Q16294; Q16608; Q59FL9; D3DVP9; D3DVQ0
• Molecular Weight: 87710
• NCBI Official Full Name: fibroblast growth factor receptor 3 isoform 1
• NCBI Official Synonym Full Names: fibroblast growth factor receptor 3
• NCBI Official Symbol: FGFR3
• NCBI Official Synonym Symbols: ACH; CEK2; JTK4; CD333; HSFGFR3EX
• NCBI Protein Information: fibroblast growth factor receptor 3
• UniProt Protein Name: Fibroblast growth factor receptor 3
• Protein Family: Fibroblast growth factor receptor
• UniProt Gene Name: FGFR3
• UniProt Synonym Gene Names: JTK4; FGFR-3

NCBI Description

This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. [provided by RefSeq, Aug 2017]

Uniprot Description

FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer.

Protein type: EC 2.7.10.1; FGFR family; Kinase, protein; Membrane protein, integral; Protein kinase, TK; Protein kinase, tyrosine (receptor); TK group

Chromosomal Location of Human Ortholog: 4p16.3

Cellular Component: cell surface; endoplasmic reticulum; extracellular region; focal adhesion; Golgi apparatus; integral component of plasma membrane; nucleus; plasma membrane; transport vesicle

Molecular Function: 1-phosphatidylinositol-3-kinase activity; ATP binding; fibroblast growth factor binding; fibroblast growth factor-activated receptor activity; identical protein binding; phosphatidylinositol-4,5-bisphosphate 3-kinase activity; protein binding; protein tyrosine kinase activity; Ras guanyl-nucleotide exchange factor activity

Biological Process: bone maturation; bone mineralization; cell-cell signaling; chondrocyte differentiation; chondrocyte proliferation; endochondral bone growth; endochondral ossification; fibroblast growth factor receptor apoptotic signaling pathway; fibroblast growth factor receptor signaling pathway; MAPK cascade; negative regulation of developmental growth; peptidyl-tyrosine phosphorylation; phosphatidylinositol phosphorylation; positive regulation of cell proliferation; positive regulation of ERK1 and ERK2 cascade; positive regulation of MAPK cascade; positive regulation of phosphatidylinositol 3-kinase activity; positive regulation of phospholipase activity; positive regulation of protein kinase B signaling; positive regulation of tyrosine phosphorylation of STAT protein; protein autophosphorylation; skeletal system development

Disease: Achondroplasia; Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans; Bladder Cancer; Camptodactyly, Tall Stature, And Hearing Loss Syndrome; Cervical Cancer; Colorectal Cancer; Crouzon Syndrome With Acanthosis Nigricans; Hypochondroplasia; Lacrimoauriculodentodigital Syndrome; Muenke Syndrome; Nevus, Epidermal; Testicular Germ Cell Tumor; Thanatophoric Dysplasia, Type I; Thanatophoric Dysplasia, Type Ii